CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2007-04-02): Shorter treatment effective for HCV genotype 2

Clinical

Shorter treatment effective for HCV genotype 2

Last Updated: 2007-04-02 17:11:31 -0400 (Reuters Health)

NEW YORK (Reuters Health) - For patients with chronic hepatitis C virus genotype 2 who achieve a rapid virologic response at 4 weeks, 16 and 24 weeks of treatment with peginterferon and ribavirin are equally efficacious, according to researchers.

"The recommended treatment for patients with hepatitis C virus genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks," Dr. Wan-Long Chuang, of Kaohsiung Medical University Hospital, Taiwan, and colleagues write in the April issue of the journal Gut.

In the present study, the researchers examined whether a 16-week treatment with peginterferon and ribavirin is as effective as a standard 24-week treatment. Patients with HCV2 were randomly assigned in a 1:2 ratio to 16 weeks (n = 50) or 24 weeks (n =100) of treatment with peginterferon alpha-2a and ribavirin. The subjects were followed for 24 weeks after the end of the treatment.

The initial response rate was 86% in the 16-week group and 87% in the 24-week group. The rate of sustained response was 94% in the 16-week group and 95% in the 24-week group. Patients in the 16-week group had a higher relapse rate than those in the 24-week group (6% versus 3.1%, respectively), but the difference did not reach significance.

Early response, patient age, "but not treatment duration, were independent factors associated with sustained viral response," Dr. Chuang and associates note.

Both treatment arms were well tolerated. There were no serious adverse events reported. Both groups had similar rates of adverse events with the exception of alopecia, which was significantly higher in the 24-week group.

Gut 2007;56:553-559.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.